All terms in DRUGBANK

Label Id Description
Didanosine DB00900 [A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.]
Remogliflozin etabonate DB12935 [Remogliflozin etabonate has been used in trials studying the treatment and basic science of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2.]
Human rabies virus immune globulin DB11603 [IMOGAM Rabies Pasteurized is indicated for post-exposure prophylaxis in persons suspected of exposure to rabies, who have not previously received a complete immunization regimen with a cell culture produced rabies vaccine. Persons previously vaccinated with other types of rabies vaccines in whom adequate antibody levels have not been demonstrated should receive full post-exposure prophylaxis with RIG and a cell culture-produced rabies vaccine. IMOGAM Rabies Pasteurized should be administered promptly after exposure, in conjunction with rabies vaccine. If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies vaccine. Since rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun. Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory Committee on Immunization Practices (ACIP), and the World Health Organization (WHO).]
Hydroxyethyl cellulose DB11602 [Hydroxyethyl cellulose is a polysaccharide derivative with gel thickening, emulsifying, bubble-forming, water-retaining and stabilizing properties. It is used as a key ingredient in many household cleaning products, lubricants and cosmetics due to its non-ionic and water-soluble nature. It is often used as an ingredient in ophthalmic pharmaceutical preparations such as artificial tear solutions and adjunct agent in topical drug formulations to facilitate the delivery of drugs with hydrophobic character.]
Tuberculin Purified Protein Derivative DB11601 [Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines.]
Quercetin-3'-O-phosphate DB12937 [Quercetin-3'-O-phosphate has been used in trials studying the treatment of Insulin Resistance and Impaired Glucose Tolerance.]
Isoxaflutole DB12938 [Balance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.]
Beeswax DB11600 [The wax obtained from the honeycomb of the bee. It consists primarily of myricyl palmitate, cerotic acid esters and some high-carbon paraffins. Beeswax is used as a stiffening agent in ointments and creams, and enables water to be incorporated to produce water-in-oil emulsions. It is also used as a coating in the manufacture of modified-release oral preparations]
Efmoroctocog alfa DB11607 [Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as [DB13999][A31551]. It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups. Haemophilia A is a rare bleeding disorder associated with a slow clotting process caused by the deficiency of factor VIII. Patients with this disorder are more susceptible to recurrent bleeding episodes and excessive bleeding following minor traumatic injuries or surgical procedures [A31551]. Prophylactic treatment may dramatically improve the management of severe haemophilia A in the future by reducing joint bleeding and other hemorrhages that cause chronic pain and disability to patients [A31551, A31552]. Prophylaxis has also shown to reduce the formation of neutralizing anti-FVIII antibodies, or inhibitors [A31552]. Factor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood clot. Efmoroctocog alfa is a first commercially available rFVIII-Fc fusion protein (rFVIIIFc) where the conjugated molecule of rFVIII to polyethylene glycol is covalently fused to the dimeric Fc domain of human immunoglobulin G1, a long-lived plasma protein [FDA Label]. The B domain of factor VIII is deleted. In animal models of haemophilia, efmoroctocog alfa demonstrated an approximately two-fold longer t½ than commercially available rFVIII products [A31551]. Other drug products with similar structure and function to Efmoroctocog alfa include [DB13999], which is produced by recombinant DNA technology and is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function, and [DB13192], which is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits. It is commonly marketed as Elocta or Eloctate for intravenous injection. To date, no confirmed inhibitory autoantibodies were seen in previously treated patients included in clinical studies and treatment-emergent adverse events were generally consistent with those expected in the patient populations being studied [A31551]. The extended half-life of efmoroctocog alfa provides several clinical benefits for patients, including reduced frequency of injections required and improved adherence to prophylaxis [A31551].]
Fenobam DB12931 [Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome).]
Susoctocog alfa DB11606 [Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the activated partial thromboplastin time (aPTT) assay, a conventional in vitro test for biological activity of factor VIII. Patients with AHA have normal Factor VIII genes for coagulation pathways but develop inhibitory autoantibodies directed against Factor VIII. These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this procoagulant protein. Susoctocog alfa serves to temporarily restore the inhibited endogenous Factor VIII for effective hemostasis. In a global, prospective, controlled, multi-center Phase 2/3 open-label clinical trial, all patients responded to susoctocog alfa treatment within 24 hours [L1129]. Susoctocog alfa is a glycoprotein containing a 90 kDa heavy chain and a 80 kDa light chain with the naturally-occuring B domain replaced with a twenty-four amino acid linker. Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection. It is the first recombinant porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and safety by measuring factor VIII activity levels in addition to clinical assessments [L1129]. The recombinant porcine sequence allows less susceptibility to inactivation by circulating human factor VIII antibodies.]
Merotocin DB12932 [Merotocin has been used in trials studying the treatment of Preterm Delivery.]
Myrrh DB11605 [Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora abyssinica, Burseraceae.]
RO-4987655 DB12933 [RO4987655 has been used in trials studying the treatment of Neoplasms.]
Granotapide DB12934 [Granotapide has been used in trials studying the treatment of Type II Diabetes Mellitus.]
Tetanus Immune Globulin DB11604 [Tetanus Immune Globulin is manufactured from human plasma [FDA Label]. It contains antibodies against tetanus toxoid and is primarily used as prophylaxis against tetanus in wounded patients.]
Opipramol DB12930 [Opipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.]
Felbamate DB00949 [Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.]
Norgestimate DB00957 [Norgestimate is a form of progesterone, which is a female hormone important for the regulation of ovulation and menstruation. Norgestimate is used with estradiol to treat the symptoms of menopause.]
Hydrocodone DB00956 [Hydrocodone is a synthetic opioid derivative of codeine.[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain. Historically, hydrocodone has been used as a cough suppressant although this has largely been replaced by [dextromethorphan] in current cough and cold formulations. Hydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain. The FDA first approved Hydrocodone for use as part of the cough suppressant syrup Hycodan in March of 1943.[L9025]]